Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | CFTR | P13569 | 7/20 | 0.48 |
| ▸ | CLPP | Q16740 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5257725 | 0.91 | ACHE (0.48) | ACHECFTRCLPPALDH1A1TP53 | |
| SCHEMBL10150024 | 0.90 | ACHE (0.47) | ACHECFTRCLPPALDH1A1TP53 | |
| SCHEMBL786424 | 0.88 | ACHE (0.45) | ACHECFTRCLPPALDH1A1TP53 | |
| SCHEMBL802330 | 0.82 | ACHE (0.49) | ACHECLPPALDH1A1TP53 | |
| SCHEMBL13054956 | 0.82 | CLPP (0.44) | ACHECFTRCLPPALDH1A1TP53 | |
| SCHEMBL13963037 | 0.82 | ACHE (0.48) | ACHECLPP | |
| SCHEMBL5255808 | 0.81 | IGF1R (0.52) | ACHETP53EGFRMEN1KMT2A | |
| SCHEMBL801470 | 0.81 | ACHE (0.43) | ACHECLPP | |
| SCHEMBL786842 | 0.80 | HTR2A (0.57) | EGFR | |
| SCHEMBL10150037 | 0.78 | USP1 (0.46) | ACHECFTRCLPPALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633210-B2 | Triazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-21 | — | — | US | disclosed |
| US-8524720-B2 | Substituted N-(pyrazol-5-yl)-pyrrolo[3,2-D]pyrimidin-4-amine useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-03 | — | — | US | disclosed |
| US-20120071657-A1 | TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120040935-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS | VERTEX PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040935-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS | VERTEX PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-7968545-B2 | Compositions useful as inhibitors of voltage-gated ion channels | VERTEX PHARMACEUTICALS INC. (US) | 2011-06-28 | — | — | US | disclosed |
| US-7968545-B2 | Compositions useful as inhibitors of voltage-gated ion channels | VERTEX PHARMACEUTICALS INC. (US) | 2011-06-28 | — | — | US | disclosed |
| US-7951820-B2 | Triazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-05-31 | — | — | US | disclosed |
| EP-1317448-B2 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMA (US) | 2011-05-04 | — | — | EP | disclosed |
| US-20100256170-A1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-10-07 | — | — | US | disclosed |
| US-6660731-B2 | Alzheimer's disease; anticancer agents; antidiabetic agents | VERTEX PHARMACEUTICALS INCORPORATED | 2003-12-09 | — | — | US | disclosed |
| US-6638926-B2 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-10-28 | — | — | US | disclosed |
| US-6613776-B2 | Protein serine/threonine kinase inhibitors used for treating diseases such as cancer, diabetes and Alzheimer's disease | VERTEX PHARMACEUTICALS INCORPORATED | 2003-09-02 | — | — | US | disclosed |
| US-6610677-B2 | Enhancing glycogen synthesis, lowering blood levels of glucose, treating colon, ovarian, or breast cancer, treating diabetes, treating schizophrenia | VERTEX PHARMACEUTICALS INCORPORATED | 2003-08-26 | — | — | US | disclosed |
| US-20030083327-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-05-01 | — | — | US | disclosed |
| US-20030078166-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-04-24 | — | — | US | disclosed |
| US-20030073687-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-04-17 | — | — | US | disclosed |
| US-20030064981-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-04-03 | — | — | US | disclosed |
| US-20030064982-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-04-03 | — | — | US | disclosed |
| US-20030055044-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064981-A1 | Pyrazole compounds useful as protein kinase inhibitors | AURKC, AURKA, GSK3A | ACHE 1592/4885CFTR 4600/4885CLPP 4435/4885 |
| US-20100256170-A1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | GSK3B, CDK3, GSK3A | ACHE 2572/4885CFTR 4622/4885CLPP 4800/4885 |
| US-20120040935-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS | KCNQ1, KCNN2, KCNH3 | ACHE 280/4885CFTR 182/4885CLPP 4126/4885 |
| US-20030064982-A1 | Pyrazole compounds useful as protein kinase inhibitors | MAP3K20, CDK2, MAP2K2 | ACHE 2301/4885CFTR 4669/4885CLPP 4708/4885 |
| US-20030083327-A1 | Pyrazole compounds useful as protein kinase inhibitors | AURKC, AURKA, GSK3B | ACHE 931/4885CFTR 4556/4885CLPP 4642/4885 |
| US-20120071657-A1 | TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | GSK3B, GSK3A, CDK19 | ACHE 946/4885CFTR 4567/4885CLPP 4510/4885 |
| US-20030055044-A1 | Pyrazole compounds useful as protein kinase inhibitors | AURKC, AURKA, GSK3B | ACHE 1463/4885CFTR 4841/4885CLPP 4437/4885 |
| US-20030073687-A1 | Pyrazole compounds useful as protein kinase inhibitors | AURKC, AURKA, GSK3B | ACHE 2766/4885CFTR 4766/4885CLPP 4831/4885 |
| US-20030078166-A1 | Pyrazole compounds useful as protein kinase inhibitors | GSK3B, GSK3A, GSKIP | ACHE 964/4885CFTR 4131/4885CLPP 4208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.